WO2005058064A1 - アスタキサンチン配合ペット用食物 - Google Patents
アスタキサンチン配合ペット用食物 Download PDFInfo
- Publication number
- WO2005058064A1 WO2005058064A1 PCT/JP2004/018950 JP2004018950W WO2005058064A1 WO 2005058064 A1 WO2005058064 A1 WO 2005058064A1 JP 2004018950 W JP2004018950 W JP 2004018950W WO 2005058064 A1 WO2005058064 A1 WO 2005058064A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- astaxanthin
- pet
- acid
- pet food
- food
- Prior art date
Links
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 87
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 86
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 86
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 86
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 85
- 235000013305 food Nutrition 0.000 title claims abstract description 76
- 230000007958 sleep Effects 0.000 claims abstract description 29
- 150000002148 esters Chemical class 0.000 claims abstract description 23
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 22
- 206010012655 Diabetic complications Diseases 0.000 claims abstract description 12
- 230000001877 deodorizing effect Effects 0.000 claims abstract description 11
- 230000003405 preventing effect Effects 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims description 49
- 230000035945 sensitivity Effects 0.000 claims description 19
- 241000282326 Felis catus Species 0.000 claims description 11
- 241000283690 Bos taurus Species 0.000 claims description 5
- 241000282693 Cercopithecidae Species 0.000 claims description 5
- 241000270322 Lepidosauria Species 0.000 claims description 5
- 241001494479 Pecora Species 0.000 claims description 5
- 241000700159 Rattus Species 0.000 claims description 5
- 241000270295 Serpentes Species 0.000 claims description 5
- 241000699800 Cricetinae Species 0.000 claims description 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 4
- 241000272875 Ardeidae Species 0.000 claims description 3
- 241000700199 Cavia porcellus Species 0.000 claims description 3
- 210000003899 penis Anatomy 0.000 claims description 3
- 241000009328 Perro Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000016776 visual perception Effects 0.000 claims 1
- 230000006872 improvement Effects 0.000 abstract description 25
- 210000003608 fece Anatomy 0.000 abstract description 17
- 230000004438 eyesight Effects 0.000 abstract description 10
- 210000002700 urine Anatomy 0.000 abstract description 8
- 230000008447 perception Effects 0.000 abstract description 7
- 238000004332 deodorization Methods 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 230000019771 cognition Effects 0.000 abstract 2
- 239000000284 extract Substances 0.000 description 41
- 241000282472 Canis lupus familiaris Species 0.000 description 21
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 16
- 235000019645 odor Nutrition 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- 235000014113 dietary fatty acids Nutrition 0.000 description 14
- 239000000194 fatty acid Substances 0.000 description 14
- 229930195729 fatty acid Natural products 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 229940088594 vitamin Drugs 0.000 description 13
- 229930003231 vitamin Natural products 0.000 description 13
- 235000013343 vitamin Nutrition 0.000 description 13
- 239000011782 vitamin Substances 0.000 description 13
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 12
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 150000003722 vitamin derivatives Chemical class 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 150000004665 fatty acids Chemical class 0.000 description 10
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 239000011732 tocopherol Substances 0.000 description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 9
- -1 Astaxanthin diesters Chemical class 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 150000005690 diesters Chemical class 0.000 description 8
- 235000013372 meat Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229960003512 nicotinic acid Drugs 0.000 description 8
- 235000001968 nicotinic acid Nutrition 0.000 description 8
- 239000011664 nicotinic acid Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 229960001295 tocopherol Drugs 0.000 description 8
- 230000000007 visual effect Effects 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000033764 rhythmic process Effects 0.000 description 6
- 235000012424 soybean oil Nutrition 0.000 description 6
- 239000003549 soybean oil Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000002177 Cataract Diseases 0.000 description 5
- 208000017442 Retinal disease Diseases 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 150000004671 saturated fatty acids Chemical class 0.000 description 5
- 235000003441 saturated fatty acids Nutrition 0.000 description 5
- 208000019116 sleep disease Diseases 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000001384 succinic acid Substances 0.000 description 5
- 229930003799 tocopherol Natural products 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- GZIFEOYASATJEH-UHFFFAOYSA-N 2,8-dimethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- 235000019733 Fish meal Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 235000010724 Wisteria floribunda Nutrition 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001747 carotenoids Chemical class 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000002781 deodorant agent Substances 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000004467 fishmeal Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229940057059 monascus purpureus Drugs 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 229940042585 tocopherol acetate Drugs 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 4
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 241000238424 Crustacea Species 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 244000098338 Triticum aestivum Species 0.000 description 3
- 206010047571 Visual impairment Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 230000003930 cognitive ability Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000004377 improving vision Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000010871 livestock manure Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 208000029257 vision disease Diseases 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 3
- CUXYLFPMQMFGPL-BGDVVUGTSA-N (9Z,11E,13Z)-octadecatrienoic acid Chemical compound CCCC\C=C/C=C/C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-BGDVVUGTSA-N 0.000 description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 235000009434 Actinidia chinensis Nutrition 0.000 description 2
- 244000298697 Actinidia deliciosa Species 0.000 description 2
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000132092 Aster Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000195628 Chlorophyta Species 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 235000019735 Meat-and-bone meal Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 208000003464 asthenopia Diseases 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- IJTNSXPMYKJZPR-UHFFFAOYSA-N parinaric acid Chemical compound CCC=CC=CC=CC=CCCCCCCCC(O)=O IJTNSXPMYKJZPR-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 235000012437 puffed product Nutrition 0.000 description 2
- 235000014102 seafood Nutrition 0.000 description 2
- 230000008786 sensory perception of smell Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 2
- 235000019150 γ-tocotrienol Nutrition 0.000 description 2
- 239000011722 γ-tocotrienol Substances 0.000 description 2
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical class OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- CGFPNELNAZZYQL-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;sulfuric acid Chemical compound OS(O)(=O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CGFPNELNAZZYQL-RXSVEWSESA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- MQZIGYBFDRPAKN-OXBRSLPGSA-N (6r)-6-hydroxy-3-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-18-[(4r)-4-hydroxy-2,6,6-trimethyl-3-oxocyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound C([C@@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@H](O)CC1(C)C MQZIGYBFDRPAKN-OXBRSLPGSA-N 0.000 description 1
- MQZIGYBFDRPAKN-GNBIBNSWSA-N (6s)-6-hydroxy-3-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-18-[(4r)-4-hydroxy-2,6,6-trimethyl-3-oxocyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound C([C@@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-GNBIBNSWSA-N 0.000 description 1
- DTRGDWOPRCXRET-UHFFFAOYSA-N (9Z,11E,13E)-4-Oxo-9,11,13-octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCC(=O)CCC(O)=O DTRGDWOPRCXRET-UHFFFAOYSA-N 0.000 description 1
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- DTRGDWOPRCXRET-SUTYWZMXSA-N (9e,11e,13e)-4-oxooctadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCC(=O)CCC(O)=O DTRGDWOPRCXRET-SUTYWZMXSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WXBXVVIUZANZAU-UHFFFAOYSA-N 2E-decenoic acid Natural products CCCCCCCC=CC(O)=O WXBXVVIUZANZAU-UHFFFAOYSA-N 0.000 description 1
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 1
- FPAQLJHSZVFKES-UHFFFAOYSA-N 5-Eicosenoic acid Natural products CCCCCCCCCCCCCCC=CCCCC(O)=O FPAQLJHSZVFKES-UHFFFAOYSA-N 0.000 description 1
- FPAQLJHSZVFKES-FOCLMDBBSA-N 5E-eicosenoic acid Chemical compound CCCCCCCCCCCCCC\C=C\CCCC(O)=O FPAQLJHSZVFKES-FOCLMDBBSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000609240 Ambelania acida Species 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- FBFZPSQPKNIVMT-ZAFYKAAXSA-N Ascorbic acid 3-sulfate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1OS(O)(=O)=O FBFZPSQPKNIVMT-ZAFYKAAXSA-N 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 235000011960 Brassica ruvo Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003301 Ceiba pentandra Nutrition 0.000 description 1
- 244000146553 Ceiba pentandra Species 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 241000965477 Darksidea delta Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- GZZPOFFXKUVNSW-UHFFFAOYSA-N Dodecenoic acid Natural products OC(=O)CCCCCCCCCC=C GZZPOFFXKUVNSW-UHFFFAOYSA-N 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- XDBMXUKHMOFBPJ-ZAFYKAAXSA-N L-ascorbic acid 2-sulfate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OS(O)(=O)=O)=C1O XDBMXUKHMOFBPJ-ZAFYKAAXSA-N 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241001542817 Phaffia Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 241001647091 Saxifraga granulata Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000592344 Spermatophyta Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000006364 Torula Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000077233 Vaccinium uliginosum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- JPBAVLUULZJFFO-JENHRLMUSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O JPBAVLUULZJFFO-JENHRLMUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- CUXYLFPMQMFGPL-SUTYWZMXSA-N all-trans-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-SUTYWZMXSA-N 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- IJTNSXPMYKJZPR-WVRBZULHSA-N alpha-parinaric acid Natural products CCC=C/C=C/C=C/C=CCCCCCCCC(=O)O IJTNSXPMYKJZPR-WVRBZULHSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- MQZIGYBFDRPAKN-UWFIBFSHSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-UWFIBFSHSA-N 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 239000010905 bagasse Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 229940055416 blueberry extract Drugs 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 239000010474 borage seed oil Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- KJDZDTDNIULJBE-QXMHVHEDSA-N cetoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCCCC(O)=O KJDZDTDNIULJBE-QXMHVHEDSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- RFCSPHPIGYWVCG-UHFFFAOYSA-N docos-5-enoic acid Chemical compound CCCCCCCCCCCCCCCCC=CCCCC(O)=O RFCSPHPIGYWVCG-UHFFFAOYSA-N 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical class OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical class COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000002974 melatonin derivative Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- WXBXVVIUZANZAU-CMDGGOBGSA-N trans-2-decenoic acid Chemical compound CCCCCCC\C=C\C(O)=O WXBXVVIUZANZAU-CMDGGOBGSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CUXYLFPMQMFGPL-UYWAGRGNSA-N trichosanic acid Natural products CCCCC=C/C=C/C=CCCCCCCCC(=O)O CUXYLFPMQMFGPL-UYWAGRGNSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 235000019144 δ-tocotrienol Nutrition 0.000 description 1
- 239000011729 δ-tocotrienol Substances 0.000 description 1
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention has an effect of deodorizing excrement such as urine and feces, an effect of improving sleep, an effect of improving sensitivity such as perception and cognitive ability, an effect of improving vision, and a treatment, improvement, and prevention effect of diabetes and diabetic complications.
- Pet foods such as mice, rats, guinea pigs, egrets, monkeys, dogs, cats, hamsters, pigs, cows, sheep, horses, penguins, snakes, lizards and birds containing astaxanthin and Z or its esters Things.
- Astaxanthin is a kind of carotenoid same as i3_carotenoid, and it is a crustacean such as shrimp and riki, fish such as salmon and Thailand, algae such as matococcus green alga, and yeasts such as red yeast fafia. It is a red pigment with a rich dietary experience that is widely distributed in nature, especially in the ocean.
- astaxanthin has a potent antioxidant action 100-100,000 times that of vitamin ⁇ ( ⁇ -tocopherol) and about 40 times that of ⁇ -toxin. Astaxanthin has been expected from the industry as a health food since the time of treatment.
- Other functional properties of astaxanthin include anti-inflammatory, anti-atherosclerotic, anti-diabetic, protective retinal effects against light damage, circadian rhythm regulation, immunostimulation, anti-stress, and muscle retention Numerous reports have been made on the effects of improving sperm quality and suppressing bladder cancer induction. In addition, as effects on skin, effects of inhibiting pigmentation, inhibiting melanin production, and inhibiting photoaging have been reported.
- astaxanthin and / or its ester power Deodorant effect of excretion of urine and feces of pet, sleep improvement effect, sensitivity improvement effect such as perception and cognitive ability, visual improvement effect, treatment of diabetes and diabetic complications ⁇ Improvement ⁇ It is known to have a preventive effect.
- Pet foods having a sleep improving effect include a composition comprising tributophan and a carbohydrate for promoting onset of sleep in animals (see Patent Document 5), and a mammal containing a novel melatonin derivative as an active ingredient. And a pharmaceutical composition for treating an age-related behavioral disorder of a pet animal containing an acetylcholinesterase 'inhibitor (see Patent Document 7).
- Patent Document 7 also describes administration of an acetylcholinesterase ′ inhibitor that improves the sensitivity of pets.
- Patent Document 2 Japanese Patent Application Laid-Open No. 3-266943
- Patent Document 3 Japanese Patent Application Laid-Open No. 2001-258480
- Patent Document 4 JP-A-2002-114690
- Patent Document 5 JP-A-58-201715
- Patent Document 6 JP-A-7-196493
- Patent Document 7 JP-A-2000-309545
- Patent Document 8 U.S. Pat.No. 5,527,533
- Patent Document 9 International Publication No. 02/094253 pamphlet
- Patent Document 10 JP-A-10-276721
- the present invention provides a mouse having a deodorizing effect of excrement such as feces and urine of a pet, a sleep improving effect, a sensitivity improving effect, a visual improving effect, a treatment, an improvement and a prevention effect of diabetes and diabetic complications.
- the purpose of the present invention is to provide food for pets such as horses, rats, guinea pigs, egrets, monkeys, dogs, cats, wild cats, mustards, pigs, cows, sheep, horses, horses, snakes, lizards and birds.
- the inventors conducted research on the above points, and as a result, it was found that astaxanthin and / or its ester deodorize the excrement of feces and urine of pets, improve sleep, improve sensitivity, and improve vision.
- the present invention was found to have an effect, a treatment, an improvement and a prevention effect for diabetes and diabetic complications, and completed the present invention.
- the present invention has been made based on such findings.
- Pet food characterized by containing astaxanthin and Z or its ester
- Pet food according to (1) which has a sleep improving effect comprising astaxanthin and Z or an ester thereof.
- Pet food according to (1) which has a visual improvement effect comprising astaxanthin and / or an ester thereof.
- the pet is at least one of a mouse, a rat, a guinea pig, a heron, a monkey, a dog, a cat, a hamster, a pig, a cow, a sheep, a horse, a penis, a snake, a lizard, and a bird ( 1) One (6) food for pets and
- the odor of the excrement of the pet is reduced, the sensitivity of the pet is improved, and the reaction to humans is improved. Is more noticeable and the pet sleeps better to improve health, improve vision, It can treat, improve, and prevent diabetic complications, and can better keep pets.
- astaxanthin means a product derived from a natural product or obtained by synthesis.
- Natural products include, for example, crustaceans such as shrimp, krill and riki, shells and eggs and organs of various species, skins and eggs of various seafood, algae such as green alga Hematococcus, and yeasts such as red yeast Phaffia. And those obtained from seed plants such as marine bacteria, eubacterium, fukusou and kinbori. Extracts and synthetic compounds from nature are commercially available and readily available.
- Astaxanthin can be obtained, for example, by culturing red yeast puffer, green alga Hematococcus, marine bacteria and the like in an appropriate medium according to a known method.
- Matococcus is most suitable for green algae because of its low cultivation and extraction, the highest concentration of astaxanthin, and high productivity.
- a culture method for obtaining a green algae having a high astaxanthin content of matococci a closed culture method in which foreign microorganisms are mixed and the propagation of other contaminants is small is preferred, for example, a closed dome.
- a method for culturing using a culture medium having a shape, a conical or cylindrical culture device and a gas discharge device movable in the device (see WO 99/50384), or a closed culture device
- the method of culturing by irradiating light from the inside with a light source and the method of culturing in a plate-shaped culture tank are suitable.
- astaxanthin is contained in an oil-soluble organic solvent such as acetone, alcohol, ethyl acetate, benzene, and chloroform from natural products containing astaxanthin.
- the components can be extracted. After the extraction, the solvent is removed according to a conventional method to obtain a mixed concentrate of monoestenol-type astaxanthin and diester-type astaxanthin. The concentrate obtained may be further purified if desired.
- Astaxanthin can be used in the form of extract of astaxanthin obtained by the above method and a powder or an aqueous solution containing the same, or a dried product such as red yeast fafia, green alga matococcus and marine bacteria. Those crushed products can be used.
- Astaxanthin is 3,3'-dihydroxy-, one carotene-1,4 dione and has a stereoisomer. Specifically, three stereoisomers of (3R, 3'R) -astaxanthin, (3R, 3'S) -astaxanthin and (3S, 3'S) -astaxanthin are known. Either of these forces can be used in the present invention.
- astaxanthin includes astaxanthin and / or an ester thereof. Further, esters of astaxanthin include monoester and / or diester forms.
- Astaxanthin is known to be a highly safe compound with no mutagenicity observed.
- the pet food containing astaxanthin of the present invention as an active ingredient at least one of a free form, a monoester form, and a diester form of astaxanthin can be used. Since the ester form has two hydroxyl groups protected by an ester bond, it is physically more stable than the free form and the monoester form and is less susceptible to oxidative degradation in pet food. However, it is considered that when taken into a living body, it is rapidly hydrolyzed to astaxanthin by an in-vivo enzyme, and shows an effect.
- Examples of the monoester of astaxanthin include lower or higher saturated fatty acids or esters esterified by lower or higher unsaturated fatty acids.
- Specific examples of the lower or higher saturated fatty acids or lower or higher unsaturated fatty acids include acetic acid, lauric acid, myristic acid, pentadecanoic acid, palmitic acid, palmitooleic acid, heptadecanoic acid, elaidic acid, ricinoleic acid, betroceric acid, Batacenoic acid, Eleostearic acid, Punicic acid, Licanic acid, Parinaric acid, Gadoric acid, 5-Eicosenoic acid, 5-Docosenoic acid, Cetolic acid, Erucic acid, 5,13-Docosagenic acid, Seracholic acid, Decenoic acid, Examples include steric acid, dodecenoic acid, oleic acid, stearic acid, eicosapentaenoic acid, docosa
- amino acids such as glycine and alanine
- Monovalent or polyvalent carboxylic acids such as acetic acid and citric acid
- inorganic acids such as phosphoric acid and sulfuric acid
- sugars such as darcoside
- sugar fatty acids such as glycemic sugar fatty acid and sphingosaccharide fatty acid
- fatty acids such as glycemic fatty acid
- Monoesters esterified with glyceric phosphoric acid or the like can be given.
- salts of the monoesters are also included.
- Astaxanthin diesters include the lower saturated fatty acids, higher saturated fatty acids, lower unsaturated fatty acids, higher unsaturated fatty acids, amino acids, mono- or polycarboxylic acids, inorganic acids, sugars, sugar fatty acids, fatty acids And diesters esterified with the same or different acids selected from the group consisting of glycerol and phosphoric acid.
- the salts of the diesters are also included.
- Examples of the diester of glycerol phosphoric acid include saturated fatty acid esters of glyceric phosphoric acid and glycerol phosphates containing fatty acids selected from higher unsaturated fatty acids, unsaturated fatty acids and saturated fatty acids. And so on.
- antioxidants include, for example, vitamin Es (tocopherols), vitamin Cs, carotenoids, polyphenols, oils containing unsaturated fatty acids, and other natural extracts.
- Vitamin Es include vitamin E, tocotrile and derivatives thereof. It is good to use an oil containing at least one of them as vitamin Es.
- Specific examples of vitamin Es include dl ⁇ -tocopherol, d ⁇ -tocopherol, dl ⁇ -tocopherol acetate, d- ⁇ -tocopherol acetate, dl_ct-tocopherol succinate, d- ⁇ -tocopherol succinate Nore, nicotinic acid dl- ⁇ -tocopherolone, nicotinic acid d- ⁇ -tocopherolone, d // 3-tocopherol, d-j3-tocopherol, dl- / 3-tocopherol acetate, d_ ⁇ -tocopherol acetate, succinic acid dl_ ⁇ -tocopherol, succinic acid d_ ⁇ -tocopherol, nicotinic acid tocopherol, nicotinic acid d_i3-to
- tocopherol d_ [delta] - tocopherol, acetic DL_ .delta. tocopherol acetate d_ .delta. tocopherols, succinic acid dl - ⁇ -tocopherol, succinic acid d_ ⁇ -tocopherol, nicotinic acid dl- ⁇ -tocopherol nore, nicotinic acid d_ ⁇ -tocopherol, ⁇ -tocotrienole, monotocotrienol, ⁇ -tocotrienol, ⁇ -tocotrienol And the like.
- dl- ⁇ -tocopherol acetic acid dl-one-tocopherol, succinic acid dl-one-tocopherol, nicotinic acid dl-one-tocopheronele, one-tocotrienole, / 3-tocotrienole, ⁇ - Tocotrienol is preferred.
- Vitamin Cs include vitamin C and its derivatives.
- Vitamin C derivatives include, for example, glycosides such as ascorbic acid darcoside, L-asconorevir palmitate, L-ascorbyl isopalmitate, L-ascorbyl dipalmitate, and L-ascorbyl diisopalmitate.
- carotenoids examples include ⁇ -carotene, ⁇ -carotene, lycopene, rutin, canthaxanthin, astaxanthin, zeaxanthin, one apo-1 8'-carotene derived from Rikuguchi tinnerore and donariella, carrot, palm oil, And tomato pigments.
- Unsaturated fatty acid-containing oils include unsaturated fatty acids such as linoleic acid, arachidonic acid, polylinolenic acid, eicopentaenoic acid, and docosahexanoic acid, dali celloids containing these unsaturated fatty acids, and unsaturated fatty acids of these unsaturated fatty acids.
- Oils containing phospholipids such as sesame oil, sesame oil, kiwi seed oil, camellia oil, barley oil, grape seed oil, black plant oil, borage seed oil, evening primrose oil, large Hemp oil, corn oil, soybean oil, linseed oil, butter, lard, coconut oil, coconut oil, olive oil, canola oil, fresh safflower, fish oil and the like.
- Other natural extracts include escozuki kogi extract, kiwi extract, Clara extract, cake extract, Hongjing heaven extract, coffee extract, wheat extract, saishin extract, peony extract, Sempukuka extract, Tsukimiso extract, tomato extract, grape extract, black power plant extract, spinach power extract, merosuria extract, okuinin extract, artea extract, Ibukitorano extract, nettle extract, and chinko extract Extract, oak extract, oak extract, seaweed extract, gentian extract, Scutellaria extract, confectionery extract, perilla extract, honeysuckle extract, cinnamon extract, bean tea extract, corn extract, saxifrage Extract, rosemary extract, Remoko extract, foliage extract, blueberry extract, etc. It is.
- the ratio of astaxanthin to the above-mentioned antioxidant varies depending on the type of astaxanthin / antioxidant to be blended, but is usually 1 part by weight of astaxanthin.
- the antioxidant is 0.1 to 200 parts by weight, preferably 0.2 to 20 parts by weight, preferably 1 part by weight of astaxanthin.
- the antioxidant is antioxidant to 1 part by weight of astaxanthin.
- the agent is 0.5-5 parts by weight.
- the pet food of the present invention containing astaxanthin has an effect of deodorizing pet excrement, improving sleep, improving sensitivity, improving vision, and treating, improving and preventing diabetic and diabetic complications. Can be used for purpose.
- the excrement deodorizing effect in the present invention refers to deodorization, deodorization and deodorization of pet excrement, and by providing pet food containing astaxanthin, the malodor of pet manure is significantly reduced. It is to be reduced to. Astaxanthin inhibits intestinal bacteria and plant-derived proteases that decompose urea, which generates ammonia, which is the main cause of foul odors, and promotes the growth of useful intestinal bacteria by improving the intestinal environment. It is considered that there is.
- the sleep improving effect of the pet in the present invention is an effect of improving, treating, and suppressing sleep disorders caused by stress, illness, changes in life rhythm, taking drugs, physical illness, aging, and the like.
- Sleep disorder refers to insomnia such as difficulty falling asleep and difficulty falling asleep. Difficulty in sleep is that the person wakes up many times in the night and sleeps shallowly, wakes up midnight, wakes up near dawn and cannot sleep until morning, ⁇ early awakening '', Symptoms such as difficulty in feeling sleep I can get lost.
- the effect of improving the sensibility of a pet in the present invention means that impairment of perception or cognitive ability caused by stress, illness, changes in living rhythm, aging, etc. is improved, treated, or suppressed. For example, respond sensitively to sounds or strangers, or be happy when the owner acts or feeds the pet to get the pet's attention. And the tendency of pets to draw attention to their owners, and to increase the likelihood of giving appropriate greetings to their owners. Improving the physical condition has the effect of improving the fur, etc.
- the visual improvement effect of a pet in the present invention means that visual impairment caused by stress, illness, change in life rhythm, aging, etc. is improved, treated or suppressed.
- Visual impairment includes disorders such as refractive errors such as myopia, hyperopia, astigmatism and presbyopia, dysregulation, retinopathy, maculopathy, glaucoma, cataract, dry eye, conjunctivitis, and other disorders such as fatigue. It also has the effect of preventing eyestrain.
- the treatment, improvement, and prevention effects of pet diabetes in the present invention include diabetes due to an increase in blood sugar level due to lifestyle predisposition such as excessive administration of food and lack of exercise due to indoor preservation, in addition to genetic predisposition. It means that the complication is treated, ameliorated or prevented.
- the present invention is effective for both type I diabetes and type II diabetes, but more effective for type II diabetes. Insulin resistance, a characteristic of type II diabetes arising from acquired factors, is often associated with obesity, especially visceral fat accumulation, and is often accompanied by hyperlipidemia and hypertension.
- the pet food of the present invention treats, ameliorates or prevents diabetes by improving hyperglycemia, that is, reducing elevated blood glucose levels.
- the pet food of the present invention also has the effect of preventing, ameliorating, and preventing amelioration of diabetes by treating and improving nervous disorders, retinal disorders, nephropathy, and ischemic diseases, which are complications of diabetes.
- neuropathy sudden deafness, abnormalities of the eyes and face (paralysis and pain), orthostatic hypotension, diarrhea and constipation (digestive symptoms), dysuria, pain in the extremities, abnormal sensation, muscle atrophy, Treatment of gangrene Effective for 'improvement' prevention.
- it is effective against macular degeneration, glaucoma, cataract, simple retinopathy, preproliferative retinopathy and proliferative retinopathy. It is also effective in preventing ⁇ improvement '' in the treatment of cerebral infarction and myocardial infarction in ischemic diseases.
- the pet food of the present invention also has the effect of preventing, ameliorating, and preventing amelioration of diabetes by treating and improving nervous disorders, retinal disorders, nephropathy, and
- the pet food of the present invention may be in the form of a solid preparation, solid, pellet, granule, biscuit, paste, dry food, semi-dry food (for example, pet food having a water content of about 10 to 50% by weight). ) Or wet food such as canned food (eg, pet food having a water content of about 50% by weight).
- astaxanthin can be added to a pet food material and mixed at an appropriate step, or an aqueous solution of astaxanthin can be sprinkled on pet food to produce it.
- the pet food of the present invention can also be prepared by adding and mixing astaxanthin to a commercially available pet food or sprinkling it.
- human nutritional supplements it is manufactured in solid preparations such as tablets, sublingual tablets, pills, powders, powders, fine granules, granules, capsules and soft capsules that are easy to ingest. be able to.
- Raw materials that can be blended with pet food are not particularly limited as long as they can be used as pet food.
- conventional ingredients such as fish meal, fish meat, seafood, fish meal, animal meat, meat meal, meat-and-bone meal, blood meal, feather meal, silkworm chaff oil meal, skim milk powder, etc.
- Animal fats such as beef oil, pork oil, bone oil
- animal raw materials such as chicken eggs, milk, etc .
- microorganisms such as brewer's yeast and torula yeast
- corn, maize, wheat, barley, rye, oats Cereals such as wheat flour, brown rice, brown rice, soybeans, kinako, cassava
- starches such as alpha-uniform starch and starch
- soybean oil cake, dehulled soybean oil cake, rapeseed oil cake, laccase oil cake, coconut oil cake, sunflower oil cake, amaji Oil cakes such as oil cake, sesame oil cake, safari oil cake, palm kernel oil cake, kapok oil cake, etc .
- glucan feed dalten meal, starch cake
- Manufacturing lees such as honey, soy sauce lees, beer lees, beet pulp, bagasse, tofu lees, malt root, mandarin peel
- Examples of the raw materials that can be blended with the solid preparation include, in addition to the above-mentioned raw materials, carriers generally used in the field of human foods, for example, by uniformly mixing the carrier and astaxanthin. The ability to do S.
- Specific examples of the carrier include sucrose, sorbitol, and fructo.
- Sugars such as sugars, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, rapeseed oil, olive oil and soybean oil, and flavors such as strawberry flavor and peppermint.
- excipients such as ratatose, dalicose, sucrose, lactose, mannitol, corn starch, silicon dioxide, starch, sodium alginate, etc.
- Disintegrants such as magnesium stearate, talc, binders such as polybutyl alcohol, hydroxypropyl cellulose, gelatin, casein, glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, saponin, lecithin Emulsifiers such as guar gum, alginic acid, carrageenan, agar, thickeners such as pectin, gum arabic, crystalline cellulose, and plasticizers such as glycerin can also be used. Tablets and soft capsules are preferred because they are easy to consume.
- the pet food may contain additives such as fortifying agents, quality improving agents, antibiotics, antibacterial agents, enzymes, fungicides, antioxidants, coloring agents, sweeteners, and flavors, if necessary. It may be.
- the content of astaxanthin in pet food is not particularly limited, and can be selected within a range that does not impair palatability.
- the content of pet food can be reduced. 0.0001 to 10% by weight, preferably 0.0005 to 5% by weight, and more preferably 0.0005 to 3% by weight, based on the total amount.
- a solid preparation in which the dose per administration or per day can be specified.
- the amount of astaxanthin in one solid preparation weighing 200 to 100 mg is free. It is 0.1 to 10 mg, preferably 0.2 to 5 mg in terms of astaxanthin.
- the dose of the pet food to the pet can be selected according to age, weight, and the like.
- 1 to 500 zgZ days per kg of body weight preferably 2300 zg / Day, more preferably about 5 to 200 xg / day.
- the administration time may be any time, and the number of administrations may be once or multiple times per day.
- Pets are animals that have been improved by humans for pets, not for food, and have many opportunities for human contact.
- Specific examples of the pet include a mouse, a rat, a guinea pig, a heron, a monkey, a dog, a cat, a hamster, a pig, a cow, a sheep, a horse, a penis, a snake, a lizard, a bird, and the like.
- Astaxanthin in the following examples is an astaxanthin oil containing an extract from Hematococcus algae manufactured by Fuji Chemical Industry Co., Ltd.
- Astaryl 50F (trade name, manufactured by Fuji Chemical Industry Co., Ltd.) in the following examples is an oil composed of a fatty acid ester of astaxanthin and 5% in terms of free astaxanthin, and a tridaliceride, [Product name, manufactured by Fuji Chemical Industry Co., Ltd.] is a powder containing 20% of Astalril 50F.
- Each of the 29 dogs (weighing 2.227 kg) was bred for 1 month by a commercial dog hood instead of a special diet. Thereafter, the same dog food and a tablet containing astaxanthin (containing lmg in terms of a free substance of astaxanthin, manufactured by Meniwan Co., Ltd.) were both given for one month. The diet was given one astaxanthin-containing tablet per meal twice a day.
- Table 1 shows the results of evaluating whether the degree of deep sleep at night, the sensitivity to external stimuli, and the sight after the one-month administration were improved compared to those before administration.
- Example 2 In the same manner as in Example 1, eight cats (body weight: 5.88 kg) were given tablets containing astaxanthin for 1 month (containing lmg in terms of a free form of astaxanthin, manufactured by Meniwan Co., Ltd.).
- Table 2 shows the results of the evaluation of whether the degree of deep sleep at night, the sensitivity to external stimuli, and the vision were improved compared to before administration.
- the odor of each sample was measured by an odor measuring device (KALMOR-II, manufactured by Kalmore). Specifically, 280mm X 200mm sealed vinyl Insert the measurement probe into the bag, measure the odor (initial value) in the plastic bag that does not contain the sample, then put the weighed lOOmg sample into the plastic bag, and after 15 minutes have passed, force the vinyl containing the sample. The odor (measured value) in the bag was measured, and the initial value of the measured value power was subtracted to obtain the odor value.
- KALMOR-II manufactured by Kalmore
- a beagle dog (a body weight of about 10 kg, 6 months old) of a diabetes mellitus model produced by administering streptozotocin (STZ) purchased from Sankyo Laboratories Co., Ltd.
- STZ streptozotocin
- One tablet 300 mg containing 0.67 mg of free astaxanthin] was mixed in the feed and administered for 4 weeks. Blood was collected at the start of the test, two weeks and four weeks after the start, blood serum was separated, and the blood glucose level was measured.
- Beagle dogs are housed in metal cages, bred under conditions of temperature 22 soil 2 ° C, humidity 55 ⁇ 10%, lighting 12 hours (7 am to 7 pm) and daily Fed with food.
- Beagle dogs were 6 months old (weight about 10 kg) and purchased from Sankyo Laboratories Co., Ltd. After the purchase, the animals were preliminarily reared for about 4 weeks, and were used after confirming that there was no abnormality in the general condition, body weight, and food consumption during that time.
- Vedanore dogs are housed in metal cages, kept at a temperature of 22 ⁇ 2 ° C, a humidity of 55 ⁇ 10%, and illuminated for 12 hours (7 am to 7 pm). Fed with food.
- Example 6 Astar reel powder
- the tablets were tableted with HT-AP18SS-II) to prepare tablet-type pet food.
- the above components were mixed and granulated using a disc pellet granulator (manufactured by Fuji Padal Co., Ltd.) to prepare 100-300 mg (size 4 mm ⁇ X about 5-10 mm). This pellet was dried at 50 ° C for 10 hours to obtain dry food.
- a disc pellet granulator manufactured by Fuji Padal Co., Ltd.
- the above components were mixed and pulverized, sieved with a sieve having an opening of lmm, and then watered so that the solid content was about 27% by weight.
- Extrusion was carried out using a cooking ethatruder (manufactured by Wenger) equipped with a round die having a diameter of 8 mm to obtain a puffed product.
- the obtained expanded product was dried at 120 ° C. for 20 minutes using a belt dryer, and then 5 parts by weight of soybean oil was sprayed on 95 parts by weight of the expanded product to obtain a dry dog food.
- Vitamin 'Mineral Mix Aster reel 50F 0.1 weight part
- each can was filled with 300g of meat along with 100g of water.
- the cans were finally retort sterilized at 120 ° C for 70 minutes.
- the can is 100mm in diameter x 120mm in height
- Each can was filled with 160g of meat along with 100g of water.
- the cans were finally retorted at 110 ° C for 80 minutes.
- Example 6 When the pet food of Examples 6 to 11 was given to a dog or a cat, they ate without any hesitation without worrying about the smell or the like. In addition, the same results as in Example 5 were obtained with respect to the excrement deodorizing effect, the sleep improving effect, the sensitivity improving effect, and the visual improving effect.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Birds (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005516375A JP4933097B2 (ja) | 2003-12-19 | 2004-12-17 | 糖尿病および糖尿病合併症の治療・改善方法 |
US10/583,482 US20070128310A1 (en) | 2003-12-19 | 2004-12-17 | Astaxanthin-containing pet foods |
US12/962,088 US8623434B2 (en) | 2003-12-19 | 2010-12-07 | Astaxanthin-containing pet foods |
US14/100,312 US9820497B2 (en) | 2003-12-19 | 2013-12-09 | Astaxanthin-containing pet foods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-422304 | 2003-12-19 | ||
JP2003422304 | 2003-12-19 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/583,482 A-371-Of-International US20070128310A1 (en) | 2003-12-19 | 2004-12-17 | Astaxanthin-containing pet foods |
US12/962,088 Continuation US8623434B2 (en) | 2003-12-19 | 2010-12-07 | Astaxanthin-containing pet foods |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005058064A1 true WO2005058064A1 (ja) | 2005-06-30 |
Family
ID=34697325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/018950 WO2005058064A1 (ja) | 2003-12-19 | 2004-12-17 | アスタキサンチン配合ペット用食物 |
Country Status (3)
Country | Link |
---|---|
US (3) | US20070128310A1 (ja) |
JP (2) | JP4933097B2 (ja) |
WO (1) | WO2005058064A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099478A1 (en) * | 2004-04-16 | 2005-10-27 | Nestec S.A. | Method and compositions for reducing oxidative stress in an animal |
JP2009007346A (ja) * | 2007-05-30 | 2009-01-15 | Toyo Shinyaku:Kk | 糖尿病併発疾病予防剤 |
JP2009011278A (ja) * | 2007-07-09 | 2009-01-22 | Hill's Pet Nutrition Inc | 糞便の体積と糞便の臭気を低減するための組成物と方法 |
JP2009501527A (ja) * | 2005-07-14 | 2009-01-22 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 動物の生命を延長するための方法 |
JP2009298740A (ja) * | 2008-06-16 | 2009-12-24 | Fuji Chem Ind Co Ltd | 認識運動機能改善組成物 |
US8193240B2 (en) | 2004-03-17 | 2012-06-05 | Nestec S.A. | Compositions and methods for reducing or preventing obesity |
US8226973B2 (en) | 2005-11-02 | 2012-07-24 | Nestec, S. A. | Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use |
US8535708B2 (en) | 2004-12-29 | 2013-09-17 | Hill's Pet Nutrition, Inc. | Methods for inhibiting a decline in learning and/or memory in animals |
US8592478B2 (en) | 2000-10-31 | 2013-11-26 | Hill's Pet Nutrition, Inc. | Antioxidant-containing food composition |
JP2014501536A (ja) * | 2011-01-14 | 2014-01-23 | ザ・アイムス・カンパニー | カロチノイドに関連する組成物及び方法 |
CN103766667A (zh) * | 2014-02-17 | 2014-05-07 | 韦业桂 | 一种家养蛇全价配合饲料及其制备方法 |
US8906434B2 (en) | 2007-07-09 | 2014-12-09 | Hill's Pet Nutrition, Inc. | Compositions and methods for reducing stool volume and stool odor |
JP2020108374A (ja) * | 2018-12-28 | 2020-07-16 | ユニ・チャーム株式会社 | 総合栄養食ペットフード |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4933097B2 (ja) * | 2003-12-19 | 2012-05-16 | 株式会社メニコン | 糖尿病および糖尿病合併症の治療・改善方法 |
US20080260892A1 (en) * | 2005-07-15 | 2008-10-23 | Fisher Feeds Limited | Animal Feed |
KR101514422B1 (ko) | 2008-05-20 | 2015-04-24 | 아주대학교산학협력단 | 해양미생물 대사체를 유효성분으로 포함하는 당뇨병 예방또는 치료용 조성물 |
JP2010270095A (ja) * | 2008-05-30 | 2010-12-02 | Yamaha Motor Co Ltd | 認知行動能力向上剤 |
US20130273176A1 (en) * | 2010-12-07 | 2013-10-17 | Nestec Sa | Methods and compositions useful for promoting sleep in animals |
CA2866184A1 (en) * | 2012-03-05 | 2013-09-12 | Gratuk Technologies Pty Ltd | Dietary supplement |
US20130295075A1 (en) * | 2012-05-03 | 2013-11-07 | Orasis | Compositions and methods of treating glaucoma |
EP3040069A4 (en) * | 2013-06-27 | 2017-04-12 | The Doshisha | Intestinal flora improving composition containing astaxanthin |
JP6064140B2 (ja) * | 2015-06-05 | 2017-01-25 | Fsk三昭株式会社 | 飼料の生産方法 |
EP3231421A1 (en) * | 2016-04-11 | 2017-10-18 | Greenaltech, S.L. | Uses of a carotenoid in the treatment or prevention of stress induced conditions |
JP2017218424A (ja) | 2016-06-08 | 2017-12-14 | アスタリール株式会社 | 認知機能向上のための運動療法において使用するための、カロテノイドを含む認知機能向上組成物 |
US11260099B2 (en) * | 2016-12-16 | 2022-03-01 | Hills Pet Nutrition, Inc. | Pet food compositions |
EP3632422B1 (en) * | 2017-05-23 | 2024-10-16 | Nissui Corporation | Composition comprising monounsaturated fatty acids having 20 or more carbon atoms for use in improving vascular endothelial function |
WO2020196557A1 (ja) * | 2019-03-28 | 2020-10-01 | 富士フイルム株式会社 | 乳化組成物及びこれを含む飲料 |
CN112515049A (zh) * | 2020-11-09 | 2021-03-19 | 南京未来宠物产业研究院有限公司 | 一种虾青素在制备功能性宠物食品中的应用 |
CN114747686A (zh) * | 2022-03-14 | 2022-07-15 | 青岛彬利宠物用品有限公司 | 一种含天然虾青素的宠物猫粮 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000507821A (ja) * | 1996-03-27 | 2000-06-27 | アスタカロテーヌ、アクチボラグ | 育種哺乳動物および生産哺乳動物の生産を増加させる因子 |
WO2003013268A1 (en) * | 2001-08-03 | 2003-02-20 | Mars Uk Limited | Foodstuff |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1204666A (en) | 1982-03-08 | 1986-05-20 | Richard J. Wurtman | Method for improving sleep |
JP2865779B2 (ja) | 1990-03-15 | 1999-03-08 | タマ生化学株式会社 | 家畜動物用飼料添加剤 |
JP2623055B2 (ja) | 1991-10-11 | 1997-06-25 | 株式会社東洋発酵 | 発酵健康飼料 |
US5654325A (en) | 1993-11-18 | 1997-08-05 | Eli Lilly And Company | Melatonin derivatives for use in treating sleep disorders |
US5527533A (en) * | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
JPH09124470A (ja) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
US6022867A (en) * | 1996-11-27 | 2000-02-08 | Showa Denko Kabushiki Kaisha | Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals |
US5937790A (en) * | 1996-12-18 | 1999-08-17 | Showa Denko Kabushiki Kaisha | Anti-stress agent for animals and a method of reducing stress in animals |
JPH10175866A (ja) * | 1996-12-18 | 1998-06-30 | Showa Denko Kk | 動物用ストレス反応緩和剤及びストレス反応の緩和方法 |
SE522246C2 (sv) * | 1997-02-27 | 2004-01-27 | Astacarotene Ab | Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion |
JPH10276721A (ja) | 1997-04-11 | 1998-10-20 | Suntory Ltd | アスタキサンチン含有飲食物 |
SE524337C2 (sv) * | 1998-10-16 | 2004-07-27 | Astacarotene Ab | Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk behandling av matsmältningsbesvär |
US6086886A (en) * | 1998-10-22 | 2000-07-11 | Jarrow Formulas, Inc. | Composition for promoting intestinal health |
EP1050303A3 (en) | 1999-04-27 | 2003-01-15 | Pfizer Products Inc. | Methods and compositions for treating age-related behavioral disorders in companion animals |
SE9903619D0 (sv) * | 1999-10-07 | 1999-10-07 | Astacarotene Ab | Use and method of treatment |
JP2001258480A (ja) | 2000-03-17 | 2001-09-25 | Ota Isan:Kk | 動物糞尿臭消臭用飼料 |
US20030104090A1 (en) * | 2000-05-05 | 2003-06-05 | Levy Pedro E. | Supplements containing annatto extracts and carotenoids and methods for using the same |
WO2001087291A1 (fr) * | 2000-05-16 | 2001-11-22 | Suntory Limited | Compositions permettant de regulariser le rythme circadien |
JP2002114690A (ja) | 2000-10-12 | 2002-04-16 | Taiyo Kagaku Co Ltd | 排便消臭剤 |
ES2292754T3 (es) * | 2001-05-24 | 2008-03-16 | Fuji Chemical Industry Co., Ltd. | Atenuacion de un error de funcion de control del ojo. |
US20030124230A1 (en) * | 2001-06-01 | 2003-07-03 | Jan Zielinski | Methods and products for bad breath |
EP1490040A4 (en) * | 2002-01-16 | 2008-03-05 | David Haines | INFLAMMATORY FORMULATIONS |
US20040151761A1 (en) * | 2003-02-05 | 2004-08-05 | The Procter & Gamble Company | Methods and compositions utilizing astaxanthin |
US20040234579A1 (en) * | 2003-05-22 | 2004-11-25 | Mark D. Finke, Inc. | Dietary supplements and methods of preparing and administering dietary supplements |
JP4933097B2 (ja) * | 2003-12-19 | 2012-05-16 | 株式会社メニコン | 糖尿病および糖尿病合併症の治療・改善方法 |
CN101095698B (zh) * | 2006-06-26 | 2010-12-01 | 青岛东海药业有限公司 | 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途 |
-
2004
- 2004-12-17 JP JP2005516375A patent/JP4933097B2/ja not_active Expired - Fee Related
- 2004-12-17 US US10/583,482 patent/US20070128310A1/en not_active Abandoned
- 2004-12-17 WO PCT/JP2004/018950 patent/WO2005058064A1/ja active Application Filing
-
2010
- 2010-12-07 US US12/962,088 patent/US8623434B2/en not_active Expired - Lifetime
-
2011
- 2011-05-02 JP JP2011102851A patent/JP2011167203A/ja active Pending
-
2013
- 2013-12-09 US US14/100,312 patent/US9820497B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000507821A (ja) * | 1996-03-27 | 2000-06-27 | アスタカロテーヌ、アクチボラグ | 育種哺乳動物および生産哺乳動物の生産を増加させる因子 |
WO2003013268A1 (en) * | 2001-08-03 | 2003-02-20 | Mars Uk Limited | Foodstuff |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8592478B2 (en) | 2000-10-31 | 2013-11-26 | Hill's Pet Nutrition, Inc. | Antioxidant-containing food composition |
US8193240B2 (en) | 2004-03-17 | 2012-06-05 | Nestec S.A. | Compositions and methods for reducing or preventing obesity |
WO2005099479A1 (en) * | 2004-04-16 | 2005-10-27 | Nestec S.A. | Methods and compositions for reducing oxidative stress in an animlal |
JP2007532121A (ja) * | 2004-04-16 | 2007-11-15 | ネステク ソシエテ アノニム | 動物における酸化ストレスを低減する方法および組成物 |
WO2005099478A1 (en) * | 2004-04-16 | 2005-10-27 | Nestec S.A. | Method and compositions for reducing oxidative stress in an animal |
US8034373B2 (en) | 2004-04-16 | 2011-10-11 | Nestec S. A. | Methods and compositions for reducing oxidative stress in an animal |
US8535708B2 (en) | 2004-12-29 | 2013-09-17 | Hill's Pet Nutrition, Inc. | Methods for inhibiting a decline in learning and/or memory in animals |
JP2009501527A (ja) * | 2005-07-14 | 2009-01-22 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 動物の生命を延長するための方法 |
US9427002B2 (en) | 2005-11-02 | 2016-08-30 | Nestec S.A. | Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use |
US8226973B2 (en) | 2005-11-02 | 2012-07-24 | Nestec, S. A. | Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use |
JP2009007346A (ja) * | 2007-05-30 | 2009-01-15 | Toyo Shinyaku:Kk | 糖尿病併発疾病予防剤 |
JP2009011278A (ja) * | 2007-07-09 | 2009-01-22 | Hill's Pet Nutrition Inc | 糞便の体積と糞便の臭気を低減するための組成物と方法 |
US8906434B2 (en) | 2007-07-09 | 2014-12-09 | Hill's Pet Nutrition, Inc. | Compositions and methods for reducing stool volume and stool odor |
JP2009298740A (ja) * | 2008-06-16 | 2009-12-24 | Fuji Chem Ind Co Ltd | 認識運動機能改善組成物 |
JP2014501536A (ja) * | 2011-01-14 | 2014-01-23 | ザ・アイムス・カンパニー | カロチノイドに関連する組成物及び方法 |
CN103766667A (zh) * | 2014-02-17 | 2014-05-07 | 韦业桂 | 一种家养蛇全价配合饲料及其制备方法 |
CN103766667B (zh) * | 2014-02-17 | 2015-06-03 | 韦业桂 | 一种家养蛇全价配合饲料及其制备方法 |
JP2020108374A (ja) * | 2018-12-28 | 2020-07-16 | ユニ・チャーム株式会社 | 総合栄養食ペットフード |
JP7423306B2 (ja) | 2018-12-28 | 2024-01-29 | ユニ・チャーム株式会社 | 総合栄養食ペットフード |
Also Published As
Publication number | Publication date |
---|---|
US9820497B2 (en) | 2017-11-21 |
US20140094524A1 (en) | 2014-04-03 |
JP2011167203A (ja) | 2011-09-01 |
JP4933097B2 (ja) | 2012-05-16 |
US8623434B2 (en) | 2014-01-07 |
US20070128310A1 (en) | 2007-06-07 |
JPWO2005058064A1 (ja) | 2007-07-12 |
US20110077307A1 (en) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4933097B2 (ja) | 糖尿病および糖尿病合併症の治療・改善方法 | |
US20100086638A1 (en) | Feed formulations containing docosahexaenoic acid | |
KR20220002796A (ko) | 반려동물용 눈 건조 개선 및 눈물 착색 예방을 위한 조성물 | |
KR20190027434A (ko) | 기호성 및 보존안정성이 개선된 반려동물용 사료의 제조방법 | |
KR102457595B1 (ko) | 항균성을 높인 반려동물용 사료 및 그 제조방법 | |
CN105410365A (zh) | 一种可替代抗生素的饲料添加剂及其应用 | |
JP4113116B2 (ja) | ペットにおいて、体重を調節し、肥満および関連障害を防止するペットフード組成物 | |
JP2005535314A (ja) | 解毒及び癌予防用の栄養組成物 | |
CN103493983B (zh) | 一种提高毛皮动物毛皮质量的饲料添加剂及其制作方法 | |
US20060189566A1 (en) | Muscle building agent and preventive or remedy for muscle weakening | |
KR102035261B1 (ko) | 사료 첨가제 조성물 | |
CN106720956A (zh) | 一种鲤鱼饲料 | |
KR102147761B1 (ko) | 메추리 품종육종 방법 | |
KR102407619B1 (ko) | 고양이 헤어볼 배출 개선용 조성물 | |
KR20080026949A (ko) | 잣나무잎을 이용한 동물사육방법 및 이를 이용하여 생산된기능성 산물 | |
CN112515049A (zh) | 一种虾青素在制备功能性宠物食品中的应用 | |
JP2006304755A (ja) | ペット用食物 | |
CN117678681B (zh) | 一种具有化毛功能宠物冻干牛蛙零食及其制备方法 | |
KR101833491B1 (ko) | 자이언트 켈프를 포함하는 기능성 사료 조성물 및 이를 이용한 가축의 사육방법 | |
DE202023000357U1 (de) | Katzenfutter mit Ginseng-Extrakt | |
CN106819576A (zh) | 有益微生物无抗生物饲料添加剂及其制备方法和应用 | |
WO2024076752A1 (en) | Food compositions for companion animals | |
KR20240048595A (ko) | 항균성을 높인 반려동물용 사료 및 그 제조방법 | |
EP4514361A1 (en) | Animal food composition comprising a source of glycyrrhizin | |
DE202023000354U1 (de) | Hundefutter mit Ginseng-Extrakt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005516375 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007128310 Country of ref document: US Ref document number: 10583482 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10583482 Country of ref document: US |